PRPO logo.png
Precipio’s Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® Technology
May 22, 2023 11:00 ET | Precipio, Inc.
NEW HAVEN, Conn., May 22, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. leveraged its proprietary HemeScreen technology as part of the diagnostic process to monitor a...
PRPO logo.png
Precipio and University of Pennsylvania Enter into Joint Collaboration Agreement for Pathology Diagnostics
September 05, 2019 09:15 ET | Precipio, Inc.
NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Specialty Diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today a major development toward expanding cancer patient access to world...
PRPO logo.png
Precipio Pathology Sales Metrics Demonstrate Continuous Improvement in Q2 2019
August 13, 2019 11:30 ET | Precipio, Inc.
NEW HAVEN, Conn., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the results of three key performance metrics that together...